Perspective Therapeutics, Inc. (CATX)
NYSE: CATX · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 1995
Who owns Perspective Therapeutics, Inc.
As filed with the SECHolders of 5% or more
10
Commodore Capital LP holds 9.9% of Common Stock, $0.001 par value, as its SCHEDULE 13G filed Feb 9, 2026 says.
Directors and officers
9
report now, of 21 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 10 named at left.
Holders of 5% or moreshare of the class, as filed
Commodore Capital LP
SCHEDULE 13G · filed Feb 9, 2026 · Common Stock, $0.001 par value
Lantheus Holdings, Inc.
SCHEDULE 13D/A · filed Sep 23, 2026 · Common Stock, $0.001 par value · 10% in Sep 4, 2026
Chen Yu
SCHEDULE 13G · filed Feb 6, 2026 · Common Stock, $0.001 par value
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 4.6% in Apr 27, 2026
Qatar Investment Authority
SCHEDULE 13G · filed Feb 5, 2026 · Common Stock SH CL B
Schultz Michael K
SCHEDULE 13G/A · filed Feb 5, 2024 · Common Stock
Johnson Frances
SCHEDULE 13G/A · filed Feb 5, 2024 · Common Stock
Millennium Management LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.001 per share · 5.3% in Jul 20, 2026
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Avidity Partners Management LP
SCHEDULE 13G · filed Mar 10, 2026 · Common Stock, $0.001 par value · 4.2% in Feb 14, 2025
Morgan Stanley
SCHEDULE 13G/A · filed May 12, 2026 · Common Stock · reported falling below 5%, from 6% in Feb 12, 2026
Fmr LLC
SCHEDULE 13G/A · filed Dec 5, 2025 · COMMON STOCK · reported falling below 5%, from 8.2% in Nov 7, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What CATX reports owning in othersstakes of 5% or more, and other ties
5 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 16, 2026.
Insider tradesForm 4
0sales
2purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10% owner | 4 | $1.1M | 0 | 0 | $0 |
| Lantheus Holdings, Inc. | 10% owner | 3 | $500,000 | 0 | 0 | $0 |
| Spoor Johan M. | Chief Executive Officer | 0 | $0 | 0 | 1 | $0 |
| Hunt Jonathan Robert | Chief Accounting Officer | 0 | $0 | 0 | 1 | $0 |
| Williamson Robert F III | director | 0 | $0 | 0 | 1 | $0 |